Tempest Therapeutics, Inc. TPST announced that it is planning to explore strategic options to advance the clinical studies on its pipeline candidates aimed at increasing stockholder value. The ...
-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation -- -- Plan to present preclinical data for EO-1022 at AACR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback